Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Treatment of lupus nephritis with anti-CD40L compounds

A compound and nephritis technology, applied in anti-inflammatory agents, anti-animal/human immunoglobulins, antibodies, etc., can solve problems such as the unpredictable effect of anti-CD40L compounds on lupus nephritis

Inactive Publication Date: 2000-03-15
BIOGEN INC
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since the vast majority of human SLE patients do not have retroviral proteins in their blood, and the effect of anti-CD40L compounds on retroviral levels is unknown, the results of therapeutic interventions in (NZB×NZW)F1 mice The effect of anti-CD40L compounds on autoantibody-associated human lupus nephritis is not predictable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of lupus nephritis with anti-CD40L compounds
  • Treatment of lupus nephritis with anti-CD40L compounds
  • Treatment of lupus nephritis with anti-CD40L compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0029] The method of the present invention includes treating, preventing, reversing or stabilizing nephritis in patients with immune syndrome or developed SLE. Treatment of such patients with compounds that block the interaction between CD40L on T cells and CD40 on B cells is thought to inhibit the production of pathogenic antibodies, thereby reducing the development and associated immune complexes. Exacerbation of nephritis-associated pathogenic autoantibody levels.

[0030] compound

[0031] Therapeutic compounds useful in the methods of the invention include any compound that blocks the interaction between CD40 located on B cells and CD40L expressed on the surface of activated T cells. Specifically contemplated anti-CD40L compounds include polyclonal and monoclonal antibodies (mAbs), as well as antibody derivatives such as chimeric molecules, humanized molecules, molecules with attenuated effector functions, bispecific molecules, and conjugates of antibodies things. In a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides methods for treating nephritis associated with immune complex disease with anti-CD40L compounds. In one embodiment, anti-CD40L compounds are administered to a patient with immune complex disease who has received a kidney allograft, to inhibit the development of immune complex glomerulonephritis within the grafted kidney.

Description

field of invention [0001] The present invention relates to the administration of anti-CD40L compounds to patients for the treatment of immune syndrome glomerulonephritis, more specifically lupus nephritis. [0002] The present invention relates to methods and compositions for treating immune syndrome glomerulonephritis. More specifically, the invention relates to compounds that bind to ligands for the CD40 surface molecule on B cells and a variety of other cells for use alone or in combination with other agents for the treatment of nephritis-associated antibody-mediated diseases such as lupus or drug-induced serum sickness), or to reduce the course, severity, symptoms or effects of such disease. According to one embodiment, the invention employs the monoclonal antibody 5c8. Background of the invention [0003] Immune syndrome is mediated by the deposition of immune complexes in certain tissues, including the glomeruli and blood vessel walls. These complexes are aggregates...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61K45/00A61K39/395A61P13/12A61P37/00C07K16/28
CPCA61K38/00A61K2039/505C07K16/2875A61P13/12A61P19/02A61P29/00A61P37/00A61P37/02A61P37/06A61P43/00A61P9/14A61K39/395
Inventor S·L·卡里德D·W·托玛斯
Owner BIOGEN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com